Novozymes Biopharma, part of Novozymes A/S, has announced that it will present the company’s latest research into the development of proteins with extended circulatory half-life.
Novozymes’ new AlbufuseFlex technology is expected to have applications in drug delivery where it may be used to tailor drug half life, thereby enhancing effectiveness while improving patient quality of life.
Dave Mead, business development director at Novozymes Biopharma, comments: “We are pleased to present our latest advances in albumin fusion technology at The Next Generation Protein Therapeutics Summit. These innovations pave the way for flexibility and efficiency to support manufacturers in developing novel drugs. The company’s new AlbufuseFlex technology illustrates an exciting new era as it can offer the potential to tailor half-life according to specific medical needs.”
Short circulatory half-life is a major challenge for the therapeutic use of many peptides and proteins. Recombinant fusions of such molecules to albumin have demonstrated significantly enhanced pharmacokinetic profiles alongside bioactivity.
Novozymes’ AlbufuseFlex technology has been developed in collaboration with The University of Oslo, Norway, a leading institution in the research of albumin and its interaction with the neonatal Fc receptor (FcRn): an interaction which saves it from the normal degradative pathway experienced by other plasma proteins. Built on Novozymes’ original Albufuse platform, AlbufuseFlex has been designed to manipulate this interaction and as a result modify the half-life of the albumin or fusion thereof. The enhanced technology also provides a delivery vehicle for molecules via conjugation to albumin, offering a broad scope of usability. The AlbufuseFlex technology has one published patent application and two patent applications awaiting
publication.
For more information, visit www.biopharma.novozymes.com
Novozymes’ new AlbufuseFlex technology is expected to have applications in drug delivery where it may be used to tailor drug half life, thereby enhancing effectiveness while improving patient quality of life.
Dave Mead, business development director at Novozymes Biopharma, comments: “We are pleased to present our latest advances in albumin fusion technology at The Next Generation Protein Therapeutics Summit. These innovations pave the way for flexibility and efficiency to support manufacturers in developing novel drugs. The company’s new AlbufuseFlex technology illustrates an exciting new era as it can offer the potential to tailor half-life according to specific medical needs.”
Short circulatory half-life is a major challenge for the therapeutic use of many peptides and proteins. Recombinant fusions of such molecules to albumin have demonstrated significantly enhanced pharmacokinetic profiles alongside bioactivity.
Novozymes’ AlbufuseFlex technology has been developed in collaboration with The University of Oslo, Norway, a leading institution in the research of albumin and its interaction with the neonatal Fc receptor (FcRn): an interaction which saves it from the normal degradative pathway experienced by other plasma proteins. Built on Novozymes’ original Albufuse platform, AlbufuseFlex has been designed to manipulate this interaction and as a result modify the half-life of the albumin or fusion thereof. The enhanced technology also provides a delivery vehicle for molecules via conjugation to albumin, offering a broad scope of usability. The AlbufuseFlex technology has one published patent application and two patent applications awaiting
publication.
For more information, visit www.biopharma.novozymes.com
